The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
Open accessAbstract
Key points: T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
Self-citationB cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778
Self-citation
Cited by
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Susanibar‐Adaniya, S., & Barta, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26151 · Cited by 388
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
Cordas dos Santos, D. M., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I. M., Subklewe, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03084-6 · Cited by 287
Challenges and new technologies in adoptive cell therapy
Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 259
Metadata
- Authors
- Garfall, A. L., Dancy, E. K., Cohen, A. D., Hwang, W.-T., Fraietta, J. A., Davis, M. M., Levine, B. L., Siegel, D. L., Stadtmauer, E. A., Vogl, D. T., Waxman, A., Rapoport, A. P., Milone, M. C., June, C. H., & Melenhorst, J. J.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2019-10-01
- Volume
- 3
- Issue
- 19
- Pages
- 2812-2815
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W2977561477
- Cited by
- 226
- References
- 2
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000600
- The paper
- Garfall, A. L., Dancy, E. K., Cohen, A. D., Hwang, W.-T., Fraietta, J. A., Davis, M. M., Levine, B. L., Siegel, D. L., Stadtmauer, E. A., Vogl, D. T., Waxman, A., Rapoport, A. P., Milone, M. C., June, C. H., & Melenhorst, J. J. (2019). T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000600
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.